Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 136

1.

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A.

Cancer Res. 2007 Mar 15;67(6):2643-8.

PMID:
17363584
[PubMed - indexed for MEDLINE]
Free Article
2.

PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.

Bouali S, Chrétien AS, Ramacci C, Rouyer M, Becuwe P, Merlin JL.

Oncol Rep. 2009 Mar;21(3):731-5.

PMID:
19212633
[PubMed - indexed for MEDLINE]
3.

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Börger ME, van Cleef PH, van Krieken JH, Punt CJ, Nagtegaal ID.

Eur J Cancer. 2010 Jul;46(11):1997-2009. doi: 10.1016/j.ejca.2010.03.036. Epub 2010 Apr 21.

PMID:
20413299
[PubMed - indexed for MEDLINE]
4.

Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.

Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.

Ann Surg. 2010 Feb;251(2):254-60. doi: 10.1097/SLA.0b013e3181bc9d96.

PMID:
20010090
[PubMed - indexed for MEDLINE]
5.

[Anti-EGFR antibody therapy for colorectal cancer].

Ishikawa T, Uetake H, Sugihara K.

Nihon Rinsho. 2012 Dec;70(12):2152-8. Review. Japanese.

PMID:
23259389
[PubMed - indexed for MEDLINE]
6.

Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.

Sartore-Bianchi A, Bencardino K, Di Nicolantonio F, Pozzi F, Funaioli C, Gambi V, Arena S, Martini M, Lamba S, Cassingena A, Schiavo R, Bardelli A, Siena S.

Target Oncol. 2010 Mar;5(1):19-28. doi: 10.1007/s11523-010-0138-5. Epub 2010 Apr 11. Review. Erratum in: Target Oncol. 2012 Dec;7(4):267.

PMID:
20383783
[PubMed - indexed for MEDLINE]
7.

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.

Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A.

J Natl Cancer Inst. 2009 Oct 7;101(19):1308-24. doi: 10.1093/jnci/djp280. Epub 2009 Sep 8. Review.

PMID:
19738166
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients.

Zlobec I, Molinari F, Kovac M, Bihl MP, Altermatt HJ, Diebold J, Frick H, Germer M, Horcic M, Montani M, Singer G, Yurtsever H, Zettl A, Terracciano L, Mazzucchelli L, Saletti P, Frattini M, Heinimann K, Lugli A.

Br J Cancer. 2010 Jan 5;102(1):151-61. doi: 10.1038/sj.bjc.6605452. Epub 2009 Nov 24.

PMID:
19935791
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

[The RAS paradox of the EGFR-targeted therapy in colorectal cancer].

Tímár J, Láng I.

Magy Onkol. 2008 Jun;52(2):185-91. doi: 10.1556/MOnkol.52.2008.2.7. Review. Hungarian.

PMID:
18640895
[PubMed - indexed for MEDLINE]
10.

Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.

Derer S, Berger S, Schlaeth M, Schneider-Merck T, Klausz K, Lohse S, Overdijk MB, Dechant M, Kellner C, Nagelmeier I, Scheel AH, Lammerts van Bueren JJ, van de Winkel JG, Parren PW, Peipp M, Valerius T.

Neoplasia. 2012 Mar;14(3):190-205.

PMID:
22496619
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.

Scartozzi M, Giampieri R, Maccaroni E, Mandolesi A, Giustini L, Silva R, Zaniboni A, Biscotti T, Biagetti S, Galizia E, Loupakis F, Falcone A, Bearzi I, Cascinu S.

Ann Oncol. 2012 Jul;23(7):1706-12. doi: 10.1093/annonc/mdr558. Epub 2011 Nov 23.

PMID:
22112971
[PubMed - indexed for MEDLINE]
Free Article
12.

Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.

Ruzzo A, Graziano F, Canestrari E, Magnani M.

Curr Cancer Drug Targets. 2010 Feb;10(1):68-79. Review.

PMID:
20088793
[PubMed - indexed for MEDLINE]
13.

[Predictive biomarkers of anti-EGFR monoclonal anti-body in colorectal cancer].

Soeda H, Shimodaira H, Ishioka C.

Gan To Kagaku Ryoho. 2011 Jul;38(7):1079-83. Japanese.

PMID:
21772090
[PubMed - indexed for MEDLINE]
14.

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.

Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F.

Nat Rev Clin Oncol. 2009 Sep;6(9):519-27. doi: 10.1038/nrclinonc.2009.111. Epub 2009 Jul 28. Review.

PMID:
19636327
[PubMed - indexed for MEDLINE]
15.

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.

Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L, Lamba S, Veronese S, Frattini M, Bardelli A, Siena S.

PLoS One. 2009 Oct 2;4(10):e7287. doi: 10.1371/journal.pone.0007287.

PMID:
19806185
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.

Montagut C, Iglesias M, Arumi M, Bellosillo B, Gallen M, Martinez-Fernandez A, Martinez-Aviles L, Cañadas I, Dalmases A, Moragon E, Lema L, Serrano S, Rovira A, Rojo F, Bellmunt J, Albanell J.

Br J Cancer. 2010 Mar 30;102(7):1137-44. doi: 10.1038/sj.bjc.6605612. Epub 2010 Mar 16.

PMID:
20234366
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue.

Silvestris N, Tommasi S, Santini D, Russo A, Simone G, Petriella D, Maiello E, Tonini G, Colucci G.

Expert Opin Biol Ther. 2009 May;9(5):565-77. doi: 10.1517/14712590902870394 . Review.

PMID:
19368524
[PubMed - indexed for MEDLINE]
18.

Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.

László L.

Magy Onkol. 2010 Dec;54(4):383-94. doi: 10.1556/MOnkol.54.2010.4.13.

PMID:
21163770
[PubMed - indexed for MEDLINE]
Free Article
19.

KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.

Messner I, Cadeddu G, Huckenbeck W, Knowles HJ, Gabbert HE, Baldus SE, Schaefer KL.

J Cancer Res Clin Oncol. 2013 Feb;139(2):201-9. doi: 10.1007/s00432-012-1319-7. Epub 2012 Sep 27.

PMID:
23015072
[PubMed - indexed for MEDLINE]
20.

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, Engelman JA.

Cancer Discov. 2012 Mar;2(3):227-35. doi: 10.1158/2159-8290.CD-11-0341. Epub 2012 Jan 16.

PMID:
22448344
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk